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Abstract
Myoblast differentiation and fusion to multinucleated muscle cells can be studied in myoblasts grown in culture. Calpain
 2q .Ca -activated thiol protease induced proteolysis has been suggested to play a role in myoblast fusion. We previously
 .showed that calpastatin the endogenous inhibitor of calpain plays a role in cell membrane fusion. Using the red cell as a
model, we found that red cell fusion required calpain activation and that fusibility depended on the ratio of cell calpain to
calpastatin. We found recently that calpastatin diminishes markedly in myoblasts during myoblast differentiation just prior
 .to the start of fusion, allowing calpain activation at that stage; calpastatin reappears at a later stage myotube formation . In
 .the present study, the myoblast fusion inhibitors TGF-b , EGTA and calpeptin an inhibitor of cysteine proteases were used
to probe the relation of calpastatin to myoblast fusion. Rat L8 myoblasts were induced to differentiate and fuse in
serum-poor medium containing insulin. TGF-b and EGTA prevented the diminution of calpastatin. Calpeptin inhibited
fusion without preventing diminution of calpastatin, by inhibiting calpain activity directly. Protein levels of m-calpain and
m-calpain did not change significantly in fusing myoblasts, nor in the inhibited, non-fusing myoblasts. The results indicate
that calpastatin level is modulated by certain growth and differentiation factors and that its continuous presence results in
the inhibition of myoblast fusion. q 1997 Elsevier Science B.V.
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1. Introduction
The formation of skeletal muscle during embry-
onic development involves the commitment of multi-
potent mesodermal cells to give rise to myoblasts.
Myoblasts withdraw from the cell cycle, differentiate
and fuse to form multinucleated muscle cells. My-
oblast differentiation and fusion to multinucleated
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myotubes can be achieved in myoblasts grown in
w xprimary or cell line cultures 1–3 by altering the
extracellular medium e.g. deprivation of serum fac-
. 2qtors, addition of insulin . Myoblast fusion is Ca -de-
w xpendent 2–4 . Myoblast differentiation in tissue cul-
ture can be modulated and inhibited by some growth
w xfactors 4–6 .
 2qCalpain intracellular, Ca -dependent thiol pro-
.tease has been proposed to play an essential role in
myoblast fusion. It has been suggested that the reor-
ganization of cell membrane and cytoskeleton com-
ponents, which appears to be necessary for myoblast
0167-4889r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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w xfusion, involves calpain-induced proteolysis 3,7–10 .
Two major calpain isozymes are known, m-calpain
and m-calpain isozymes activated by mM and mM
2q w x.Ca , respectively 11,12 . The isozymes are dimers
and are composed of two different subunits, a cat-
alytic 80 kDa subunit, unique to each isozyme and a
w x30 kDa subunit, common to both 11,12 . Increased
 .m-calpain protein and activity has been found in
extracts of fusing myoblasts in primary chick and rat
embryonic myoblast cultures, as compared with that
w xfound in extracts of undifferentiated cells 7–9 . In-
creased m-calpain activity was found in fusing my-
w xoblasts in cultures of rat myoblast line L6 10 .
Fusion was inhibited by cell penetrating calpain in-
w xhibitors 8,10 .
Calpain is widely distributed in a variety of cells,
along with its endogenous inhibitor, calpastatin
w x11,12 . We have shown that the calpain–calpastatin
system plays a role in membrane fusion, by using red
w xcells as an experimental model 13–15 . We have
found that calpain-induced degradation of certain
membrane proteins is a prerequisite for the red cell
membrane fusion and that the fusibility depends on
w xthe ratio of the cellular calpain to calpastatin 14,15 .
Autolytic activation of calpain has been shown to
w xoccur in the fusing red cells 16 . In a recent study on
w xrat L8 myoblasts 17 we found that the protein levels
of m-calpain and m-calpain do not change very much
during myoblast differentiation and fusion, whereas
calpastatin diminishes significantly just prior to fu-
sion and reappears when myotubes have been formed
w x17 .
In order to further probe the relation of calpain and
calpastatin behavior to myoblast differentiation and
fusion, we employed several types of reagents which
w xinhibit myoblast fusion 4–6,8–10 . We show here
that inhibition of myoblast differentiation at early
 .stages by TGF-b and by EGTA prevents the
diminution in calpastatin. In contrast, inhibition of
fusion by the cysteine protease inhibitor calpeptin
does not prevent calpastatin diminution, so that under
these conditions fusion appears to be inhibited by
direct inhibition of calpain activity. The results indi-
cate that myoblast calpastatin level is modulated by
certain growth and differentiation factors and that its
continuous presence results in inhibition of myoblast
fusion, an inhibition that is also achieved by phar-
macological calpain inhibitors.
2. Materials and methods
2.1. Myoblast culture
Rat myoblast L8 cell line was obtained from Dr.
D. Yaffe the Weizmann Institute of Science, Re-
.hovot, Israel . The cells were grown in 0.1% gelatin-
coated 90 mm Petri dishes in Waymouth medium,
supplemented by 15% F.C.S., 1% antibiotics and 1%
 .glutamine growth medium and induced to differen-
w xtiate, as described previously 17 . Briefly, when the
number of cells reached about 50% confluency, the
medium was changed to DMEM, supplemented by
2% horse serum, 1% antibiotics, 1% glutamine and 4
 .units of insulinr100 ml medium fusion medium .
The fusion medium was replaced every 48 h. For
 .inhibition of fusion, TGF-b1 TGF-b, Sigma, USA ,
w x EGTA or calpeptin 10 a gift from Dr. T. Tsujinaka,
Osaka University Medical School, Suita, Osaka,
.Japan were added to the fusion medium, then replen-
ished every 48 h, along with the replacement of the
fusion medium. The inhibitors were used at final
concentrations of 0.3–0.5 nM TGF-b diluted from
.an aqueous solution of 1.0 mM , 1.5 mM EGTA, or
15–25 mM calpeptin diluted from a stock solution
w x.of 10 mM in DMSO 10 . For the estimation of the
extent of fusion, the cells were washed, fixed and
stained with Giemsa. The percent of fused cells was
estimated by counting nuclei in myotubesrtotal of
400–500 nuclei.
2.2. Preparation of cell extracts
The cells in the Petri dishes were washed with
PBS, then harvested with PBS containing 5 mM
EDTA. Cells were centrifuged, then lysed in a solu-
tion containing 20 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1% Triton X-100, 2.5 mM EDTA, 2.5 mM
EGTA, 0.1 mM AEBSF p-aminoethylbenzene-
sulfonyl fluoride, water soluble alternative to the
.serine protease inhibitor PMSF and 10 mg of apro-
toninrml solution. Samples were kept in ice for 30
min, then centrifuged at 8000=g. Protein concentra-
tion in the supernatants was determined by the method
w xof Lowry 18 . Aliquots of supernatants were mixed
with Laemmli sample buffer for SDS-PAGE and
immunoblotting analysis.
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2.3. Immunoblotting procedures
SDS-PAGE was carried out according to standard
procedures, using 10% acrylamide. Samples contain-
ing 40 mg of myoblast proteins were electrophoresed,
then transferred to membranes, with nitrocellulose
 .membranes Gelman used for m-calpain and calpas-
tatin and positively-charged nylon membrane
 .Qiagen used for m-calpain. Blocking was carried
out in a solution containing 20 mM Tris–HCl, 150
mM NaCl, 5% low fat dry milk, 0.05% Tween-20
and 0.02% sodium azide. The membranes were then
incubated overnight with the primary antibodies, as
previously described monoclonal anti-m-calpain anti-
body, using m-calpain purified from human red cells;
polyclonal anti-m-calpain antibody, obtained in goat,
using m-calpain purified from rabbit muscle; poly-
clonal anti-calpastatin antibody, obtained in rabbit,
w x.using calpastatin purified from human red cells 17 .
Following incubation with the primary antibodies, the
membranes were washed four times with the block-
 .ing buffer lacking azide and incubated for 1 h with
the appropriate peroxidase-conjugated secondary an-
tibodies anti-mouse antibodies for m-calpain
 .Amersham , anti-goat antibody for m-calpain
 .Sigma and anti-rabbit antibody for calpastatin
 ..Sigma . Membranes were then washed exhaustively
in 20 mM Tris–HCl, 150 mM NaCl, 0.05% Tween-
20. Detection of bands was carried out with the ECL
immunoblotting detection system ECL, Amersham
.Corp. . Bands were quantified by densitometric scan-
ning.
As shown in Fig. 1, the monoclonal anti-m-calpain
antibody recognized the large subunit of m-calpain.
The polyclonal anti-m-calpain antibody recognized
the large subunit of m-calpain and the small subunit
 w x.common to both isozymes 11,12 in both.
3. Results
3.1. Effects of inhibitors on myoblast growth and
myoblast fusion
Myoblasts were first grown in growth medium,
then induced to differentiate by changing the medium
to fusion medium, as described in Section 2. The
time of the change to fusion medium was defined as
Fig. 1. Immunoblotting of purified m-calpain and m-calpain.
Monoclonal anti-m-calpain antibody and polyclonal anti-m-calpain
antibody were used for the detection of m-calpain purified from
human red cells and m-calpain purified from rabbit muscle for
.details, see Section 2 .
0 h. Myoblasts were treated with the various reagents
at the time of change from growth medium to fusion
medium, with fusion medium and reagents replen-
ished every two days. In the control cultures, my-
oblasts became confluent at about 24 h after the
change to fusion medium, followed by alignment of
myoblasts and start of fusion at about 72–96 h.
Fusion to multinucleated myotubes was observed at
 .120–168 h Fig. 2 , with 60–80% of the myoblasts
being fused under these conditions. TGF-b inhibited
fusion completely at a concentration of 0.4 nM, but
 .allowed the cells to divide Fig. 2 . EGTA also
 .inhibited fusion with fusion of 0–5% of myoblasts
and, under the conditions used 1.5 mM EGTA added
.to fusion medium containing 1.8 mM CaCl , did not2
affect the cell viability and allowed cell division to
 . continue to confluency not shown . Calpeptin a cell
w x.penetrating, cysteine protease inhibitor 10 inhibited
fusion at concentrations of 15–25 mM, with some
 .alignment noted in the inhibited cultures Fig. 2 and
with fusion of 0–5% of the cells. When added at 48 h
after the change to fusion medium, TGF-b did not
inhibit the ensuing myoblast fusion. In contrast,
calpeptin added at this time was effective in inhibit-
ing the fusion to a degree similar to that achieved by
adding calpeptin at 0 h. Inhibition of fusion by
TGF-b and EGTA was reversible upon their removal
from the cultures at 48 and at 120 h, with myoblast
fusion observed after additional culture for about 72
h. In myoblasts treated with calpeptin, inhibition of
fusion was reversed when the reagent was removed at
48 h, but no fusion was seen in myoblasts when
calpeptin was removed at 120 h and the myoblasts
kept in culture for additional 96 h.
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Fig. 2. Phase-contrast micrographs of rat L8 myoblasts. Myoblasts shown at 120 h after change of growth medium to fusion medium
without and with the addition of 0.4 nM TGF-b or 20 mM calpeptin. The inhibitors were replaced every two days, along with the
 .replacement of fusion medium for details, see Section 2 .
3.2. Effects of inhibitors on m-calpain in the cultured
myoblasts
Aliquots of myoblast extracts were elec-
trophoresed, followed by immunoblotting with anti-
 .m-calpain antibody Fig. 3 . In the control cultures,
the level of m-calpain increased between 0 and 48 h
to 120–170% of the initial levels, without further
changes at later stages; the level of m-calpain in
TGF-b treated myoblasts was similar to that of the
control cells as estimated by densitometry of three
.experiments . Similarly, no effect on m-calpain was
 .observed by EGTA, nor by calpeptin not shown .
3.3. Effects of inhibitors on m-calpain in the cultured
myoblasts
Samples were electrophoresed and immunoblotted
 .with anti-m-calpain polyclonal antibody Fig. 4 . The
Fig. 3. Detection of m-calpain by immunoblotting, using a mono-
 .clonal antibody. TGF-b 0.4 nM was added to the myoblast
cultures at the time of the change of growth medium to fusion
 .medium and replaced every two days for details, see Section 2 .
level of the m-calpain 80 kDa subunit increased
between 0 and 48 h to 130–160% of initial levels and
remained at that level without further changes in the
control cells, nor was there any detectable effect of
calpeptin on m-calpain as estimated by the
.densitometry of three experiments . Similarly, TGF-b
and EGTA did not have an effect on the level of
 .m-calpain in the cultured myoblasts not shown .
3.4. Effects of inhibitors on calpastatin in the cul-
tured myoblasts
Samples were electrophoresed and immunoblotted
with anti-calpastatin polyclonal antibody. In the con-
trol cultures, a significant diminution of calpastatin
 .to about 20–30% of initial levels was observed at
the stages of cell alignment and start of fusion;
calpastatin reappeared at a later stage and reached
70–80% of initial levels at the stage of advanced
Fig. 4. Detection of m-calpain by immunoblotting, using poly-
 .clonal antibody. Calpeptin 20 mM was added to the myoblast
cultures at the time of the change of growth medium to fusion
 .medium and replaced every two days for details, see Section 2 .
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 .  .Fig. 5. Detection of calpastatin by immunoblotting, using polyclonal antibody. TGF-b 0.4 nM or calpeptin 20 mM were added to the
myoblast cultures, as described in Section 2.
fusion as estimated by densitometry of three experi-
.ments . No diminution in calpastatin was found in
myoblasts treated with TGF-b from the time of
 .change of growth medium to fusion medium Fig. 5 ;
the level of calpastatin remained at a high level
throughout the culture period, or even increased
somewhat in the TGF-b treated cultures reaching
140–180% of initial values at 120 h, as estimated by
.densitometry of two experiments . Most of the cal-
 .pastatin about 80% of initial levels also remained in
 .EGTA-treated myoblast cultures Fig. 6 . In contrast
to the effects of TGF-b and EGTA, calpeptin did not
Fig. 6. Detection of calpastatin by immunoblotting, using poly-
 .clonal antibody. EGTA 1.5 mM was added to the myoblast
cultures, as described in Section 2.
Fig. 7. Detection of calpastatin by immunoblotting, using poly-
 .clonal antibody. Calpeptin 20 mM was added to the myoblast
cultures, as described in Section 2.
prevent a diminution in calpastatin during myoblast
 .differentiation Figs. 5 and 7 , with calpastatin dimin-
ishing to 10–30% of the initial values. Under the
experimental conditions used, a reappearance of cal-
pastatin was observed in calpeptin-treated cultures in
about 60% of the experiments five of eight experi-
ments, using calpeptin at concentrations of 15–25
.  .mM Fig. 5 . When calpeptin was removed from
these cultures at 120 h, the myoblasts did not fuse,
appeared unchanged and had calpastatin also at 96 h
 .later not shown . In the other three experiments
using similar calpeptin concentrations, with similar
.inhibition of myoblast fusion no recovery of calpas-
tatin was noted in the calpeptin-treated myoblast
 .cultures Fig. 7 and the myoblasts degenerated within
several days after removal of the reagent.
4. Discussion
Myoblast fusion is a naturally occurring process
which can be achieved in vitro and provides a conve-
nient system to study mechanisms involved in fusion
processes in general and in myoblast differentiation
and muscle formation in particular. Myoblasts grown
in culture in the presence of growth factors prolifer-
ate and do not express muscle-specific genes. Follow-
ing reduction in growth factors, cell proliferation
ceases, muscle-specific genes are induced, whereas
w xother genes are deinduced 4–6,19–22 . Myoblast
differentiation involves a sequence of events. Expres-
sion of muscle specific transcription factors is fol-
w xlowed by the expression of cell cycle inhibitors 21 ,
diminution in the expression of some proteins e.g.
w x.b- and g-actin, fibronectin, neurofilaments 5,6,22
and the appearance of muscle specific proteins e.g.
muscle-specific myosin heavy chain, a-actin, tro-
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w x.ponin, creatine kinase 4–6,20 and cell fusion. My-
oblast differentiation and fusion can be blocked by a
variety of reagents that are useful for examining the
steps and factors involved in myoblast terminal dif-
w xferentiation 1,3–10 ; depending on the cell type and
 .reagent used e.g. TGF-b, EGTA, cytochalasin B ,
the inhibiting reagent may affect myoblast differenti-
ation and fusion at various stages, affect transcription
andror processing of mRNAs, inhibit protein synthe-
w xsis, or alter membrane stability 4–6,20 .
Cell penetrating calpain inhibitors have also been
shown to inhibit myoblast fusion in several types of
w xprimary and cell line cultures 8,10,17 . Such an
effect is consistent with the known requirement for
Ca2q in myoblast fusion and with the notion that the
degradation of certain membrane proteins by acti-
w xvated calpain 3,7–10,17 is part of the membrane
reorganization that occurs in fusing myoblasts
w x2,23,24 . Since both calpain and calpastatin are dis-
w xtributed in the cytoplasm of many cells 11–13 , the
activation of calpain would necessitate release of
calpain from the inhibitory action of calpastatin
w x25,26 . In vitro studies have shown that calpain and
2q w xcalpastatin associate in the presence of Ca 27–30
and that calpastatin appears to have two sites for the
interaction with calpain, one which inhibits the bind-
ing of calpain to the cell membrane and another site
w xwhich inhibits calpain activity 31 . Calpain activa-
tion is facilitated by translocation and binding of
w xcalpain to the membrane 25,26,32–34 . One possible
way of activating calpain in vivo would be through
calpain upregulation andror preferential binding of
calpain to certain sites at the cell membrane, creating
w xlocal calpainrcalpastatin imbalance 25,26 . Another
possible way is a diminution in the level of calpas-
tatin.
It is not known how the calpain–calpastatin sys-
tem is regulated during myoblast differentiation and
how the behavior of calpastatin in these cells is
related to that of calpain. The regulation of calpas-
tatin in the myoblasts studied here appears to be
independent of that of calpain. The fact that the
protein levels of m-calpain and m-calpain do not
change significantly in the fusing myoblasts studied
here and that they are not affected by the fusion
inhibitors suggests that these calpain isozymes belong
to a group of proteins and enzymes which are known
not to change during myoblast differentiation, nor be
affected by fusion inhibitors e.g. a and b-tubulin,
w x.glyceraldehyde-3-phosphate dehydrogenase 6,22 . In
contrast, the fact that calpastatin is diminished during
myoblast differentiation suggests a differentiation-re-
lated regulation. In preliminary experiments, we found
that calpastatin mRNA is diminished significantly in
myoblasts during differentiation and reappears in the
fused ones Supino-Rosin, Barnoy, Glaser, Kosower,
.unpublished observations . Thus, calpastatin in my-
oblasts may in part be regulated in a manner similar
to the regulation of such proteins as b- and g-actin
and fibronectin, whose mRNAs are diminished in
w xdifferentiating myoblasts 5,6 . However, it should be
pointed out that the loss of calpastatin in the fusing
myoblasts is a temporary one, whereas other dein-
duced proteins do not seem to increase again in the
myotubes. Therefore, mechanisms for regulating cal-
pastatin may be different from those governing other
proteins in the differentiating myoblast.
TGF-b has been shown to inhibit myoblast differ-
w xentiation at an early stage 4–6,35 . It inhibits the
w xexpression of Myo D 36,37 and inhibits the appear-
ance of muscle-specific mRNAs and proteins e.g.
creatine kinase, myosin heavy chain, a-actin, tro-
. w xponin 4–6 . On the other hand, TGF-b prevents the
loss of some non-muscle proteins, which normally
w xdisappear during myoblast differentiation 4–6,38 . In
addition to effects on mRNA levels, TGF-b may also
influence post translational protein modifications
w x36,38 . The effects of EGTA on myoblast differenti-
ation and fusion may be different from those of
w xTGF-b 6 . EGTA has been shown to inhibit my-
w xoblast differentiation at several steps 6 . Though
myoblast fusion is inhibited in all cases by EGTA,
 .the specific stage s at which it inhibits myoblast
differentiation and the processes that are affected
may vary, depending on the cell type. In rat myoblast
lines, EGTA appears to affect translation in addition
to effects on transcription. It partially inhibits the
appearance of some muscle-specific mRNAs and in-
hibits their translation. On the other hand, mRNAs
that disappear in fusing cells, are retained in EGTA-
treated cells, albeit at lower levels than in the prolif-
erating myoblasts, with continuous synthesis of the
w xcorresponding proteins 6 . The presence of calpas-
tatin in the EGTA-treated, non-fusing cells shown
here may thus be due to EGTA effects on calpastatin
mRNA level andror on synthesis and stability of
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calpastatin. The processes responsible for the effects
of TGF-b and of EGTA in preventing the loss of
calpastatin remain to be studied.
In contrast to the prevention of calpastatin loss in
myoblasts which were inhibited from fusing by TGF-
b and EGTA, the cysteine protease inhibitor calpeptin
inhibited myoblast fusion without preventing the loss
of most of the myoblast calpastatin. Thus, calpeptin
may serve as a ‘substitute’ for the endogenous cal-
pain inhibitor. Calpeptin, in addition of inhibiting
calpain, inhibits other cysteine proteases, such as
w xcathepsin B, H and L 10 , so that participation of
these proteases in myoblast differentiation events is
possible. Cathepsin B has recently been shown to be
upregulated during early myoblast fusion and down-
w xregulated in myotubes 39 . Calpastatin is known to
w xbe a substrate for calpain 25,40 , so that the possibil-
ity that calpastatin loss is due to calpain or cathepsin
activities has to be considered. However, since
calpeptin does not inhibit the loss of most of the
calpastatin in the differentiating myoblasts, the major
part of calpastatin loss in these cells is unlikely to be
due to degradation by calpain or other cysteine pro-
teases. The participation of calpeptin-insensitive cys-
teine proteases or of other proteases in the process is
not excluded. The effects of the inhibitors are sum-
marized in Fig. 8.
Little is known about the regulation of the cal-
pain–calpastatin system in vivo. The major calpain
isozymes have recently been shown to have metabolic
half-lives of about five days in some human cell
Fig. 8. Effects of myoblast fusion inhibitors on calpain and
calpastatin levels. Calpain levels marked as q, qq; calpastatin
levels marked as 0, q, qq.
lines; calpastatin also appeared to have a long
metabolic half-life in two lines tested for calpastatin
w x41 . No information is available on the metabolic
half-life of calpain and calpastatin in differentiating
cells or in response to signal transduction. That the
calpain–calpastatin system is regulated within cells in
response to certain signals is suggested by a study on
a pituitary cell line, in which thyrotropin-releasing
 .hormone TRH induces both the translocation of
m-calpain to the membrane and a concomitant, rapid
w xup-regulation of calpastatin protein 42 ; since calpain
activation is promoted by translocation to the mem-
brane, the increased calpastatin is presumed to serve
as a feed-back system, protecting the cells from
excessive calpain action which is triggered by the
w xTRH 42 . The temporary diminution of calpastatin in
the fusing myoblasts suggests that its reappearance is
triggered by the fusion events. However, the fact that
calpastatin can reappear in non-fusing myoblasts in-
hibited by calpeptin indicates that the loss of calpas-
tatin by itself may serve as a signal for its subsequent
upregulation and reappearance, allowing for the pro-
tection of the cell proteins from calpain-induced con-
tinuous degradation. The fact that the removal of
calpeptin at the time when calpastatin has reappeared
does not reverse the inhibition of fusion supports the
conclusion for an inhibitory action of calpastatin on
myoblast fusion. The results also indicate variability
in the ability of the calpeptin-inhibited myoblasts to
regain their calpastatin level and to survive in culture.
Since in both cases i.e. those in which the calpastatin
level is regained and those in which it remains de-
.pressed a similar degree of inhibition of myoblast
fusion is obtained, the myoblast cultures may differ
in some properties that determine their susceptibility
to calpeptin. These results point to some differences,
the nature of which is unknown at present, in the
physiological state and metabolic properties of the
cultured myoblasts.
Overall, the results presented here indicate that
calpastatin level is regulated during myoblast differ-
entiation and that its diminution allows the calpain
activation required for fusion. Additional studies are
necessary to elucidate the mechanisms involved in
the regulation of calpastatin, i.e. the diminution and
reappearance of calpastatin in the fusing myoblasts
and the factors involved in the modulation of calpas-
tatin levels in fusing and non-fusing myoblasts.
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